Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Healthcare providers ...

Definition: A microarray is a small, flat substrate carrying an ordered grid of microscopic probe features, each containing a known biological molecule, that is used to measure many molecular targets ...

Congenital heart disease (CHD) is the most common type of birth defect with an incidence of approximately 10 per 1,000, ranging from 2.3 to 13.1 in 1,000 live births based on the geographic region, ...

Congenital heart disease (CHD) encompasses diseases affecting heart morphology and function due to abnormalities in the development of heart, valve, or vascular tissue structures. CHD is mainly ...

Genetic tests for Alzheimer’s can detect specific genes linked to the disease. In most cases, they can’t definitively confirm or predict a diagnosis, but they can provide insight into your relative ...

23andMe Research Institute today announced the publication of a new study highlighting the positive health actions taken by people who learned of their risk through direct-to-consumer genetic testing.

If at least two of your close family members have had a brain aneurysm, genetic testing may help identify if you’re at risk. A brain aneurysm is a bulge in one of your brain’s blood vessels. The flow ...

SEATTLE — Molecular testing has been widely integrated into mainstream healthcare, and its use is increasing in dermatology. It can help differentiate between skin conditions, for example, as some ...

Medicare Part B covers various genetic tests for diagnosing genetic conditions, identifying cancer risks, and predicting medication responses if a doctor deems them medically necessary. The cost of ...

Researchers at the University of Nottingham have developed a new genetic test that can diagnose brain tumours in as little as 2 hours. The test, called ROBIN, uses PromethION nanopore sequencing to ...

U.S. Market Expected to Hit USD 1.80 Billion by 2035; Europe Projected to Reach USD 1.67 Billion as Rare Disease Screening Programs Expand.Austin, United States, June 08, 2026 (GLOBE NEWSWIRE) -- “As ...